China’s RNA editing therapy treats muscular dystrophy in global first

Chinese LEAPER RNA Editing Technology Enters First Clinical Trial for Duchenne Muscular Dystrophy

A research team from Changping Laboratory and Peking University has published results in the journal Cell showing that a China-developed RNA editing platform successfully treated pediatric patients with Duchenne muscular dystrophy, marking the first clinical application of RNA editing for the disease.news

A New Approach to a Devastating Disease

The findings, published on Wednesday, describe two companion papers in Cell detailing the LEAPER technology and its clinical results. DMD is a severe hereditary condition caused by mutations in the gene encoding dystrophin, a protein essential for muscle function. The disease primarily affects boys and leads to progressive muscle degeneration.cell

The drug candidate, LE051, is based on the LEAPER 2.0 platform and uses circular ADAR-recruiting RNA delivered via adeno-associated virus to induce exon 51 skipping, restoring dystrophin expression in muscle cells. According to team leader Wei Wensheng, the system “can precisely locate the erroneous genetic ‘blueprint’ in muscle cells, restore the gene by removing specific sequences, and enable cells to produce functional proteins according to the corrected ‘blueprint'”.news

Unlike conventional gene therapy approaches that require delivery of foreign editing enzymes into cells, LEAPER uses only engineered RNA molecules to recruit enzymes already present in human cells, reducing the delivery burden and improving the safety profile.chinadaily

Early Clinical Results

All three pediatric patients treated in the trial demonstrated sustained improvements in motor function over a one-year follow-up period. Earlier interim data presented at a medical conference showed that the first two patients improved by three and six points, respectively, on the 34-point North Star Ambulatory Assessment and gained 61 and 25 meters on a six-minute walk test within three months of treatment. By six months, all three patients showed an eight-point increase on the assessment, maintained through at least 12 months, with a mean 96-meter gain on the six-minute walk test.precisionmedicineonline

Patients treated at the higher dose showed more than 2 percent dystrophin protein restoration in muscle biopsies at eight weeks. No dose-limiting toxicities were reported, and all adverse events were mild and transient, including headache, abdominal pain, and nausea.mdaconference

A Crowded but Critical Field

The results arrive amid a wave of genetic medicine approaches targeting DMD. Precision BioSciences recently activated its first clinical trial site for PBGENE-DMD, an in vivo gene editing therapy for the disease. Solid Biosciences has reported that its SGT-003 microdystrophin therapy produced dystrophin expression averaging 110 percent of normal levels in early patients. EdiGene, the company commercializing the LEAPER platform, has said the clinical data support continued dose exploration. By inducing exon 51 skipping, LE051 could potentially treat approximately 13 percent of DMD patients.firstwordpharma